Endometrial Polyps: Pathophysiology and Clinical Consequences

NCT ID: NCT00247923

Last Updated: 2011-07-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

1186 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-10-31

Study Completion Date

2009-02-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of these studies is to study the natural history, the symptoms of, as well as the effect of hysteroscopic resection of endometrial polyps. Furthermore, another aim is to study new diagnostic techniques to differentiate between malignant and benign endometrial polyps.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Study Part 1: New diagnostic methods for the prediction of malignancy in endometrial polyps: A prospective pilot study.

Study of angiogenesis by identification of specific angiogenesis factors in tissue biopsies from the endometrium and by Doppler ultrasound combined with IV contrast. We hope to find specific characteristics with new vessel formation in the endometrial polyp, which can play a role in the prognostic evaluation regarding the risk for cancer development. We will compare women with endometrial polyps and women with endometrial cancer to see if these methods of angiogenesis evaluation may be useful in separating benign polyps from premalignant and malignant polyps.

Study Part 2: The natural history of endometrial polyps. A prospective randomised study of patients with endometrial polyps.

Blood loss during menstruation is documented with the help of a standardized form (PBAC). The patients are randomized to hysteroscopic resection of the endometrial polyp or 6 months of observation. A new registration of blood loss during menstruation is performed by patients in both groups. In the intervention group, a new gynaecological examination 6 months after the resection documents the presence of residual polyp or symptoms. The other group is examined again after 6 months of observation. Symptoms and findings with the second examination are compared with symptoms and findings at the first examination, any changes are documented and the final outcome in the to groups are compared.

Study Part 3: The occurrence and natural history of asymptomatic endometrial polyps in perimenopausal women. A prospective controlled study.

Registration of blood loss during menstruation is documented with the help of a standardized form (PBAC) and gynaecological examination including SIS of 1000 randomly selected women in the age group 45-50. Where endometrial polyps are identified, we document the size and number of polyps and an endometrial biopsy is taken. After including a woman with an endometrial polyp in the study, the next woman without endometrial polyp is recruited to the control group. After one year, blood loss during menstruation is registered again, and all women with endometrial polyps as well as the control group have a new examination including vaginal ultrasound, SIS and endometrial biopsy. Symptoms and findings are compared with symptoms and findings at the first examination and all changes are documented. If the woman has a persistent endometrial polyp when examined at 1 year, she is offered treatment with hysteroscopic polyp resection.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Endometrial Polyp Endometrial Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hysteroscopic resection of endometrial polyps. (TCRP)

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Study 1:

* Endometrial polyp (EP) group: Presence of endometrial polyp verified by vaginal ultrasound examination.
* Cancer group: Presence of endometrial cancer verified by histological examination.
* Study 2:

* Pre- or perimenopausal women.
* Presence of endometrial polyp verified by vaginal ultrasound.
* Study 3:

* EP group: Presence of endometrial polyp verified by vaginal ultrasound.
* Control group: Normal endometrium by vaginal ultrasound examination.

Exclusion Criteria

* Study 1: Earlier severe allergic reactions.
* Study 2:

* Postmenopausal patient.
* Pregnancy.
* Additional condition requiring treatment detected during examination. Malignancy or atypical hyperplasia detected by histological examination.
* Study 3:

* Previous hysterectomy.
* Pregnancy.
* Additional condition requiring treatment detected during examination. Malignancy or atypical hyperplasia detected by histological examination.
Minimum Eligible Age

16 Years

Maximum Eligible Age

90 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ullevaal University Hospital

OTHER

Sponsor Role lead

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Olav Istre, MD., PhD.

Role: PRINCIPAL_INVESTIGATOR

Department og Gynaecology, Ullevaal University Hospital, Oslo, Norway.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Gynaecologial department, Ullevaal University Hospital

Oslo, Oslo County, Norway

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Norway

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

22200205

Identifier Type: -

Identifier Source: secondary_id

PP I/II/III

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.